Currently, the specific antitumor activity of CD8+ CTLs has been demonstrated to be effective against a variety of tumor types, such as melanoma, breast cancer, lung cancer, hepatocellular carcinoma (HCC), glioblastoma, acute and chronic leukemia, and lymphoma [7]. Here, CD8A is linked to melanoma.